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Abstract Enterococci are the third most frequent cause of infective endocarditis. A high-1 
inoculum stationary phase in vitro pharmacodynamic model with simulated endocardial 2 
vegetations was used to simulate human pharmacokinetics of daptomycin 6 or 10mg/kg/day, 3 
or linezolid 600mg q12h alone and in combination with gentamicin 1.3mg/kg q12h, rifampin 4 
300mg q8h or 900mg q24h. Biofilm-forming vancomycin-susceptible Enterococcus faecalis 5 
and vancomycin-resistant E. faecium (VRE) were tested.   At 24, 48 and 72h, all daptomycin-6 
containing regimens demonstrated significantly more activity (decline in CFU/g) than any 7 
linezolid-containing regimen against biofilm-forming E. faecalis.  The addition of gentamicin 8 
to daptomycin (6 and 10mg/kg) in the first 24 hours significantly improved the bactericidal 9 
activity. In contrast, addition of rifampin delayed the bactericidal activity of daptomycin 10 
against E. faecalis; and against VRE, antagonized all regimens at 24h. Also, against VRE, 11 
addition of gentamicin to linezolid at 72h improved activity and was bactericidal. Rifampin 12 
significantly antagonized the activity of linezolid against VRE at 72h. In in vivo Galleria 13 
mellonella survival assays, linezolid and daptomycin improved survival. Daptomycin 10mg/kg 14 
improved survival significantly over linezolid against E. faecalis. Addition of gentamicin 15 
improved efficacy of daptomycin against E. faecalis and linezolid and daptomycin against 16 
VRE. We conclude that in enterococcal infection models, daptomycin has more activity than 17 
linezolid alone.  Against biofilm-forming E. faecalis, the addition of gentamicin in the first 24h 18 
causes the most rapid decline in CFU/g. Of interest, addition of rifampin delayed or 19 
antagonized activity of daptomycin against biofilm-forming E. faecalis and VRE respectively 20 
in the first 24h.  21 
  22 
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 Introduction.   23 
  Despite major advances in medicine and surgery, infective endocarditis (IE) remains a 24 
concerning disease associated with considerable morbidity and mortality.(1) Bacterial causes 25 
of IE and bacteremia have changed over the past few decades and now streptococci, 26 
staphylococci, and enterococci have emerged as the major pathogens.(2) Among these, 27 
Enterococcus has become the most challenging to treat.  Barriers in treating these infections 28 
include the need for multiple agents to demonstrate bactericidal activity and microbiological 29 
cure (1); biofilm production among these bacteria (3, 4); and resistance to the mainstays of 30 
therapy (i.e., ampicillin, penicillin, and vancomycin) (5). Biofilm production in enterococci is 31 
common in E. faecalis, with worldwide rates reported between 26-100%, and 93% reported 32 
in the US.(3) The 2005 American Heart Association recommendations for drug-resistant 33 
enterococcal IE include linezolid and quinupristin-dalfopristin, which are both bacteriostatic 34 
against enterococci.(1).  35 
  Daptomycin, at high doses, demonstrates bactericidal activity against enterococci in 36 
other types of infection, and against S. aureus in endocarditis.(6, 7) This is due to 37 
daptomycin’s  mechanism of action as it disrupts the cell-membrane potential and is growth 38 
phase independent.(8)  There is promising data demonstrating in vitro synergy with 39 
gentamicin and daptomycin combination therapy against VRE (9-13), and case reports also 40 
support these findings.(11, 14, 15)  Therefore, the addition of gentamicin, a ribosomal active 41 
agent may provide a synergistic approach in VRE IE infections.  Additionally, since E. 42 
faecalis often produce biofilm, (3)  it is of interest to evaluate daptomycin’s activity in 43 
combination with rifampin. (16-18)  Finally, since daptomycin demonstrates concentration-44 
dependent killing, evaluation of approved doses (6mg/kg) and higher doses (10mg/kg) may 45 
result in increased activity and resistance prevention, (19) as there is established efficacy in 46 
other infection types (20) with appropriate safety data. (21)  47 
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  We therefore evaluated the in vitro activity of daptomycin and linezolid alone and in 48 
combination with gentamicin or rifampin against enterococci in an in vitro model with 49 
sequestered high inoculum stationary phase infection using simulated endocardial 50 
vegetations (SEV).(20, 22, 23)  We also tested these regimens in an in vivo survival assay 51 
using Galleria mellonella larvae. We used a vancomycin-susceptible biofilm-producing E. 52 
faecalis and a vancomycin-resistant E. faecium. We also evaluated biofilm production of 53 
these isolates.   54 
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MATERIALS AND METHODS 55 
 Bacterial strains.  We evaluated a vancomycin-susceptible, ampicillin-susceptible E. 56 
faecalis, ATCC 29212 (also gentamicin-susceptible and rifampin-susceptible) and a 57 
vancomycin- resistant (VRE) E. faecium clinical isolate from the Providence Veterans Affairs 58 
Medical Center (also penicillin-resistant, gentamicin-susceptible, and rifampin resistant). Both 59 
isolates were linezolid and daptomycin susceptible. 60 
Antimicrobial agents.  Linezolid (lot# 11C03U04, 10H10Z16; Pfizer, Inc.; NY) was 61 
obtained commercially, and daptomycin was obtained from Cubist Pharmaceuticals, Inc., 62 
(Lexington, MA). Rifampin (lot 085K1929) and gentamicin (lot 050K03421, 097K06887V) 63 
were purchased from Sigma Chemical Company (St. Louis, MO).   Stock solutions of each 64 
antibiotic were freshly prepared at the beginning of each week and kept frozen at -4°C. 65 
 Medium.  As previously described, Mueller-Hinton broth (Becton Dickinson, Sparks, 66 
MD) supplemented with calcium and adjusted to physiologic conditions of 50 mg/L calcium 67 
chloride (ionized Ca; 1.03-1.23 mmol/L) and 12.5 mg/L magnesium was used for all 68 
susceptibility analyses and in vitro pharmacodynamic analyses.(24)  Bacto Tryptic Soy Broth 69 
(TSB; Becton Dickinson ) supplemented with 1% glucose and 50mg/L calcium chloride was 70 
used to optimize biofilm production in the biofilm assay.(25, 26) Colony counts were 71 
determined using Tryptic Soy Agar (TSA, Difco, Becton Dickinson).  For the in vivo study, 72 
strains were grown overnight at 30°C in brain heart infusion (BHI) with agitation. Inoculum 73 
was confirmed by plating serial dilutions on BHI agar.  74 
 Susceptibility.  Minimum inhibitory concentrations (MICs) and minimum bactericidal 75 
concentration (MBC) testing was determined at both standard (~106 CFU/mL) and high 76 
inoculum (~109 CFU/mL) in triplicate using microbroth dilution according to CLSI 77 
methods.(27).   All samples were incubated at 35o C for 24 hours prior to interpretation of 78 
results.   79 
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 Biofilm Formation. In growth conditions (media; see above) that optimize biofilm 80 
production in Enterococcus, quantification of biofilm formation was conducted using the 81 
microtiter plate assay first described by Christensen et al. (28) and modified as follows.  82 
Briefly, stationary cultures of an overnight growth of the Enterococcal strains (1% vol/vol) 83 
were diluted into fresh cation- and glucose-supplemented TSB.  The inoculated medium was 84 
dispensed into wells of sterile flat-bottom 96-well polystyrene tissue culture plates (Costar no. 85 
3596; Corning Inc., Corning, NY, USA).  Biofilm production in Enterococcus has been linked 86 
to several genes including, fsr, gelE, and sprE.(29) Previous findings support that expression 87 
of these genes were found at 24h of growth.(29)  We examined two sets of plates, incubated 88 
at 35ºC a minimum of 24h and 48h, respectively.  The attached bacteria was then fixed and 89 
stained with crystal violet.  After drying, the optical density (OD) of stained adherent bacterial 90 
films was read using a µQuant™ Microplate Spectrophotometer microtiter dish reader (Bio-91 
Tek Instruments, Inc. Winooski, Vermont, USA.). The optical density (OD) of bacterial films 92 
were classified into the following categories: no biofilm production, weakly (+), moderately 93 
(++), or strongly (+++) adherent, based upon the ODs of bacterial films (30). The test was 94 
carried out in triplicate.   The results were averaged.   95 
In vitro pharmacodynamic infection model with Simulated Endocardial 96 
Vegetations (SEVs). As previously described, organism stocks containing approximately 97 
1010 CFU/mL were prepared by inoculating 5mL test tubes of normal saline with colonies 98 
harvested from fresh overnight growth on TSA.(20, 22, 24, 31, 32)    SEVs containing 109 99 
CFU/g were prepared by combining 0.05mL of the organism suspension with 0.4mL of 100 
human cryoprecipitate antihemolytic factor (AHF) from volunteer donors (Rhode Island Blood 101 
Bank, Providence, RI), 0.05mL of aprotinin suspension, and 0.025 mL of platelet suspension 102 
(platelets mixed with normal saline, 250,000 to 500,000 platelets per clot) in 1.5 mL 103 
eppendorf tubes.  Bovine thrombin (5,000 units/mL, 50 µL), was added to each tube after 104 
  
 - 7 -   
insertion of a sterile monofilament line into the mixture.  The resultant SEVs were removed 105 
from eppendorf tubes with a sterile 21-gauge needle and introduced into the model.  This 106 
methodology results in SEVs containing approximately 3-3.5 g/dL of albumin and 6.8-7.4 107 
g/dL of total protein (22).    108 
In vitro pharmacodynamic infection model.  An in vitro infection model consisting 109 
of a 250 mL one-compartment glass apparatus with ports where the SEVs are suspended, 110 
was utilized for all simulations.  The apparatus was pre-filled with media and antibiotics were 111 
administered as boluses over a 72-hour period into the central compartment via an injection 112 
port.  The models were placed in a 35oC water bath throughout the procedure with a 113 
magnetic stir bar for thorough mixing of the drug in the model.  Fresh media was 114 
continuously supplied and removed from the model via a peristaltic pump (Masterflex, Cole-115 
Parmer Instrument Company, Chicago, IL USA) set to simulate the half-lives of the 116 
antibiotics.  Two SEVs were removed from each model at 0, 4, 8, 24, 32, 48, 56 and 72 117 
hours.  Once removed, SEVs were then immediately homogenized in trypsin, plated onto 118 
TSA, and incubated at 35oC for 24 hours before colony count enumeration.  This method 119 
results in a lower limit of detection of 2.0 log10 CFU/g (23).  Antimicrobial carryover was 120 
minimized by serial dilution (10-10,000) of plated samples in conjunction with vacuum 121 
filtration, when necessary, where samples were washed through a 0.22 µm filter with sterile 122 
water.  These filters were then plated onto TSA and incubated at 35o C for 24 hours.  123 
Colonies were counted on filter paper; the limit of detection is 1.0 log10 CFU/g.  124 
Daptomycin was administered to simulate a 6mg/kg dose (peak, 98.6µg/mL) and 10mg/kg 125 
(141 µg/mL) every 24 hours (q24h) with pump rate set to achieve a half-life of 8 hours (21, 126 
33).  Linezolid was administered to simulate 600mg q12h with a half-life of 6 hours and a 127 
peak concentration 21 µg/mL.(27)   Gentamicin was administered to simulate 1.3 mg/kg q12h 128 
(approximate: peak 6 µg/mL, trough 0.4µg/mL) a half-life of 2 hours.(24)  Rifampin was 129 
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administered to simulate a dose of 300mg q8h (approximate peak,14.5 µg/mL) and a half-life 130 
of 4 hours.(24)  Additionally, a regimen simulating rifampin 900mg once daily in combination 131 
with linezolid or daptomycin 6mg/kg was performed in duplicate to assess the effects of 132 
rifampin dosage schedule and concentration.  133 
For combination regimen experiments the elimination rate was set for the drug with 134 
the shortest half-life, the drug with the longer half-life was supplemented.   All model 135 
experiments were performed in triplicate unless otherwise noted, to ensure reproducibility.  In 136 
addition, simulations in the absence of antibiotics were performed at the shortest half-life to 137 
assure adequate growth of the organisms in the model.  138 
Pharmacodynamic Analysis.  Reductions in log10CFU/g over 72 hours were 139 
determined by plotting time-kill curves and compared between regimens.  Bactericidal activity 140 
(99.9% kill) was defined as a ≥ 3-log10CFU/g reduction in colony count from the initial 141 
inoculum.  Bacteriostatic activity was defined as a < 3-log10 CFU/g reduction in colony count 142 
from the initial inoculum while inactive was defined as no observed reductions from initial 143 
inoculum.  The time to achieve 99.9% kill was determined by non-linear regression (using a 144 
minimum of 4 data points) if r2 ≥ 0.95, or by visual inspection.    Enhancement of activity was 145 
defined as an increase in kill of ≥ 2-log10 CFU/g by combination of antimicrobials versus the 146 
most active single agent of that combination.  Improvement was defined as a 1 to 2-log10 147 
CFU/g increase in kill in comparison to the most active single agent, while combinations that 148 
result in ≥ 1-log10 bacterial growth in comparison to the least-active single agent was 149 
considered to represent antagonism.   The terms “improvement” and “enhancement” were 150 
used because our simulations involve therapeutically obtained serum concentration and this 151 
does not permit the mathematical modeling necessary to consider the standard terms 152 
“additivity” and “synergy” (34).  Indifference was defined as <1-log10 CFU/g change in activity.   153 
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Resistance. Development of resistance was evaluated for each monotherapy and 154 
combination model at 24, 48, and 72 hours.  MIC testing (using Etests) of daptomycin, 155 
linezolid, gentamicin and rifampin were conducted with isolates obtained from the 24, 48 and 156 
72 hour time points to identify any MIC shifts. Plates were examined for growth after 24 157 
hours of incubation at 35oC.  158 
Pharmacokinetic Analysis.  Samples for pharmacokinetic analyses were obtained 159 
through the injection port at 0.5, 1, 2, 4, 6, 8, and 24 hours for verification of target antibiotic 160 
concentrations.  All samples were stored at -80ºC until analysis.  Daptomycin concentrations 161 
were determined by a previously described and validated HPLC method (Center for Anti-162 
Infective Research and Development, Hartford, CT) (20).  Gentamicin concentrations were 163 
determined by a homogeneous particle-enhanced turbidmetric immunoassay (PETIA; 164 
Architect, Multigent®; Abbott Diagnostics Abbott Park, IL, USA) at the Providence Veteran 165 
Affairs Medical Center.  The gentamicin assay was known to have a range of detection of 0.3 166 
to 10.0 µg/mL and a between day sample precision and percent coefficient of variation 167 
(CV%) of 1.35% and < 2.75%, respectively. Linezolid and rifampin concentrations were 168 
evaluated using HPLC (University of Florida, Gainesville, FL) as previously described (23, 169 
24).  Only single drug concentrations were evaluated, all in duplicate.  The half-lives, 170 
maximum concentration (Cmax), and minimum concentration (Cmin) of the antibiotics were 171 
determined by the trapezoidal method utilizing PK Analyst software (Version 1.10, MicroMath 172 
Scientific Software, Salt Lake City, UT).   173 
In vivo Galleria mellonella survival assay. Efficacy of daptomycin or linezolid in 174 
enterococcal infection was tested using Galleria mellonella survival assay. Galleria 175 
mellonella caterpillars at the final-instar stage of development were acquired from the vendor 176 
(Vanderhorst Wholesale Inc., St. Mary’s, OH) and used within 7 days of shipment.  All 177 
experiments were performed according to previously described protocols with minor 178 
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modifications (35, 36). Sixteen larvae of appropriate weight (0.25-0.35g) were randomly 179 
selected to comprise each group. Larvae were inoculated with either ~4x106 CFU of E. 180 
faecalis or 7-9x106 CFU of E. faecium followed by tested drug, or PBS as control ~1 hour 181 
after inoculation.  These inocula were chosen after an initial virulence pilot study of these 182 
strains, as they were able to kill at least 90% of the larvae within 72h. One group, injected 183 
twice with PBS, and one untouched group were used as controls in each experiment.  All 184 
injections were performed with a volume of 10µL using a Hamilton syringe. After injection, G. 185 
mellonella were incubated at 37°C and survival was measured daily. Each experiment was 186 
repeated at least twice and representative experiments are presented. Any experiment with 187 
more than two dead larvae in any control group was discarded. Doses simulated free peak 188 
concentrations seen in humans of daptomycin 6mg/kg, daptomycin 10mg/kg, or linezolid 189 
600mg (Table 4). Gentamicin 1.3mg/kg and rifampin 300mg were also tested in combination 190 
with either linezolid or daptomycin 6mg/kg.  191 
Statistical Analysis.  For the in vitro model, changes in CFU/g at 8, 24, 48, and 72 hours 192 
and time to 99.9% kill were compared by two-way analysis of variance with Tukey’s Post-Hoc 193 
test.  Statistical analyses were performed using SPSS Statistical Software (Release 20 194 
SPSS, Inc., Chicago, IL). Survival in the G. mellonella model was plotted using Kaplan-Meier 195 
curves, and groups were compared using log-rank test (GraphPad Prism 5 software). For all 196 
experiments, a p value of ≤ 0.05 was considered significant.197 
  
 - 11 -   
RESULTS 198 
 Susceptibility testing. Daptomycin, linezolid, gentamicin, and rifampin MICs for the 199 
two strains of enterococci are shown in Table 1. Against E. faecalis, there was minimal 200 
increase (1 and 2 dilutions respectively) in MICs with daptomycin and linezolid in the 201 
presence of high inocula.  Against VRE faecium, there was an increase in the high inocula 202 
MICs of daptomycin and linezolid by 3 dilutions and 2 dilutions, respectively. There was 203 
minimal increase (0-2 dilution) in the gentamicin and rifampin MICs when the isolates were 204 
evaluated at high inocula. This is consistent with published studies. (10, 23).   205 
In vitro pharmacokinetics and pharmacodynamics. The pharmacokinetic 206 
parameters of the antimicrobial agents were within the targeted range and can be found in 207 
Table 2. All obtained Cmax values were within 5% of targeted. The average and standard 208 
deviation of area under the concentration-time curve (AUC) for daptomycin 6mg/kg was 209 
1028+/-36, daptomycin 10mg/kg was 1430+/-47, and linezolid was 348 +/- 16.  210 
Biofilm production.   The E. faecalis isolate is a biofilm-positive control and produced 211 
consistent biofilm (++) at 24 and 48h. The E. faecium isolate did not produce biofilm (0) at 212 
24hours and was weakly adherent (+) at 48 hours.  213 
 In vitro pharmacodynamic infection model with Simulated Endocardial 214 
Vegetations (SEVs). The antimicrobial activity of daptomycin and linezolid were evaluated 215 
alone and in combination with gentamicin or rifampin against a high inoculum (109 CFU/g) of 216 
enterococci in a simulated IE vegetation model (Figure 1). Bactericidal activity (>3 log10 217 
decrease in CFU/g) was achieved by daptomycin 6 and 10mg/kg against E. faecalis at 24h 218 
and by daptomycin 10mg/kg against E. faecium at 8h. Linezolid monotherapy did not achieve 219 
bactericidal activity against either isolate tested at any time point.  The AUC/MIC ratio for 220 
daptomycin 6mg/kg was 514-1028 (MIC range 1-2µg/mL), daptomycin 10mg/kg was 715-221 
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1430 (MIC range 1-2µg/mL), and linezolid was 348 (MIC 1µg/mL). Percent time above the 222 
MIC (%T>MIC) was 100% for daptomycin and linezolid regimens. 223 
 Against biofilm-forming E. faecalis, daptomycin-containing regimens demonstrated 224 
significantly more activity (as measured by a decline in the mean CFU/g) than linezolid-225 
containing regimens from 8 hours through the end of the experiment (p≤0.005). (Figure 1a.) 226 
Addition of gentamicin significantly increased activity for daptomycin 10mg/kg at 24h (95% CI 227 
0.954-3.4029;p=0.033).  Addition of gentamicin to daptomycin 6mg/kg was significantly more 228 
active than any other regimen tested at 8h (p≤0.001). At 24h, there was a 3log10 CFU/g 229 
difference in activity between added gentamicin or rifampin to daptomycin 6mg/kg (p=0.010), 230 
though the difference was no longer significant at 48h. There was no significant difference 231 
between linezolid monotherapy and linezolid plus rifampin or gentamicin regimens at any 232 
time point during the 72h experiment, though adding rifampin to linezolid met the definition 233 
for improvement at 72h.  Changing the schedule of rifampin dosing from 300mg three times 234 
daily to 900mg once daily had no effect on either regimen.  235 
Against VRE faecium, at 24 and 48h, daptomycin-containing regimens had 236 
significantly (p≤0.005) more activity than any of the linezolid-containing regimens (Figure 1b). 237 
Addition of gentamicin improved linezolid activity, such that at 72h, linezolid plus gentamicin 238 
is only significantly different than daptomycin 6mg/kg (the most active regimen) (95%CI 239 
0.0144-3.4556, p=0.047) out of the daptomycin-containing regimens. It was not, however, 240 
significantly more active than linezolid monotherapy. The addition of gentamicin was 241 
significantly more active than the addition of rifampin with daptomycin 6mg/kg at 24h (95%CI 242 
0.2349-2.9984, p=0.013). Rifampin antagonized all regimens at 24h. Addition of rifampin also 243 
significantly antagonized linezolid activity at 48 and 72 hours (95%CI 0.0546-3.9921, 244 
p=0.040 and 95%CI 0.0595-4.1772, p=0.040). At 72h, activity of linezolid plus rifampin was 245 
not significantly different from the growth control. Changing rifampin dosing from three times 246 
  
 - 13 -   
daily to once daily did not significantly increase activity, however linezolid plus rifampin once 247 
daily was significantly more active than the growth control at 72h (95%CI 0.1546-4.6654, 248 
p=0.028).   249 
Gentamicin and rifampin monotherapy did not demonstrate any significant activity 250 
against either isolate during the study.  Resistance occurred in the rifampin and gentamicin 251 
monotherapy models by 24h.  The linezolid and daptomycin MICs varied at each time point 252 
but never exceeded 4 µg/mL.  In combination with both daptomycin and linezolid, rifampin 253 
MICs increased throughout the 72h experiments against VRE, from 4 to >32 µg/mL. 254 
Gentamicin MICs remained constant throughout the combination regimen experiments.  255 
In vivo Galleria mellonella survival assay. Results demonstrated that all 256 
antimicrobial regimens tested improved survival in all assays (p<0.0001) (Figures 2 and 3). 257 
Against E. faecalis, monotherapy only with daptomycin 10mg/kg improved survival 258 
significantly over linezolid alone (p=0.0032) (Figure 2a).  Gentamicin added efficacy to 259 
daptomycin 6mg/kg (p=0.0361), but not to linezolid (Figure 2 c and e), as observed in the in 260 
vitro model.  Against E. faecium, gentamicin added efficacy to both daptomycin 6mg/kg and 261 
linezolid regimens (p=0.0009 and 0.0015) (Figure 3c and e). Addition of rifampin was not 262 
significant for daptomycin or linezolid against either strain (Figure 2b, d, and 3b, d). Though 263 
there was no antagonism observed for rifampin, other results concur with our IVPD findings. 264 
265 
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DISCUSSION 266 
Infective endocarditis vegetations often carry a high bacterial burden (108 - 1010 267 
organisms per gram of tissue).(37) This high bacterial density and limited blood supply to this 268 
area allow for a diminished immune response and limited antimicrobial drug access. Location 269 
of the vegetation (right-sided versus left-sided endocarditis), patient comorbidities, and 270 
surgical interventions determine treatment success. (38, 39). The ability of bacteria to form 271 
biofilms may contribute to treatment failure, as these bacteria are inherently less susceptible 272 
to antibiotics due to decreased growth rates, nutrient restriction, and adaptive stress 273 
responses.(40-43) 274 
  Endocarditis cause by enterococci requires treatment with synergistic antimicrobials; 275 
traditionally, a cell wall active agent (beta-lactam or vancomycin) and an aminoglycoside. 276 
The presence of high-level resistance to vancomycin eliminates main therapeutic options in 277 
the management of serious enterococcal infections. Currently, options for resistant E. 278 
faecalis IE include ampicillin in combination with either imipenem/cilastatin or ceftriaxone.(1)  279 
While treatment with ampicillin in combination with ceftriaxone is becoming more common 280 
against high level aminoglycoside resistant (HLAR) E. faecalis, further investigations into 281 
PK/PD activity and dosage are needed. The 2005 American Heart Association Treatment of 282 
IE guidelines recommend > 8 weeks of linezolid or quinupristin/dalfopristin monotherapy for 283 
the treatment of Native or Prosthetic Valve Enterococcal Endocarditis Caused by Strains 284 
Resistant to Penicillin, Aminoglycoside, and Vancomycin.(1)  In many cases these 285 
treatments are not ideal; linezolid has inherent bacteriostatic activity (6, 44), 286 
myelosuppression (45, 46), and documented failure in animal studies and human case 287 
reports in bacteremia and IE. (47-50)  Quinupristin/dalfopristin use is also limited  as it 288 
demonstrates inherent bacteriostatic activity against VRE (51), lack of activity against E. 289 
faecalis (6), musculoskeletal toxicities in approximately 50% of the population, and the use of 290 
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a central line for administration.(52) Daptomycin is commonly used for the treatment of VRE 291 
infections (53), although the optimal dose and combinations are unknown.  292 
Studies have shown that daptomycin demonstrates activity in enterococcal infections, 293 
and may provide an option in patients with allergies or contraindications to other therapies.  294 
In a retrospective cohort study of VRE bloodstream infections, treatment with daptomycin or 295 
linezolid demonstrated no difference in mortality; however, infection with E. faecium and 296 
concurrent treatment with rifampin or gentamicin were independent risk factors for 297 
mortality.(54)  Antagonistic activity is often observed when rifampin is added to bactericidal 298 
agents in high inoculum infections, due to high rates of mutations conferring resistance (~1 in 299 
106).(31, 55, 56)  The in vitro model demonstrated antagonism with rifampin.  The in vivo 300 
model used a lower bacterial burden, so antagonism from rifampin resistance may not be as 301 
evident. In contrast, previous in vitro studies have shown synergy with daptomycin and 302 
rifampin, and non-antagonism with daptomycin and gentamicin.(6)   303 
G. mellonella is an invertebrate model host that shares many of the advantages of 304 
mammalian models while being free of the ethical and logistical constraints that accompany 305 
their use.(57) Specifically, G. mellonella larvae can grow in 37°C thus effectively simulating 306 
human temperatures and can be directly injected with the tested inoculum and compounds 307 
thus allowing for exact quantification of the experimental concentrations.(58) As a result, this 308 
model host is well established in the screening of the efficacy and safety of antimicrobial 309 
compounds against a variety of infections (59), and has also been effectively used to test 310 
antibiotics against Enterococcus spp. in the past.(60) G. mellonella possess both cellular and 311 
humoral defenses and have extensive structural and functional similarities to vertebrate 312 
immune systems.(61) Finally, G. mellonella larvae have also been proven effective in 313 
identifying immunomodulatory properties of several compounds that would have otherwise 314 
gone unnoticed in in vitro experiments.(62) Our in vivo model demonstrated improvement 315 
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with addition of gentamicin to daptomycin 6mg/kg.  It is possible that this improvement would 316 
not be seen with higher daptomycin doses, as survival was 100% at 9 days with the 10mg/kg 317 
dose.  318 
Another in vitro model with simulated endocardial vegetations by Hall et al. 319 
successfully demonstrated the concentration-dependent activity of daptomycin against VRE, 320 
supporting doses >6mg/kg/day, as well as demonstrating daptomycin activity superior to that 321 
of linezolid.(32) A recent meta-analysis of VRE bacteremia demonstrated a trend toward 322 
increased survival with linezolid treatment over daptomycin.(63) These differences, however, 323 
were not statistically significant, and the studies used suffered from problems of different 324 
definitions of mortality, low doses of daptomycin (average dose ~6mg/kg), and a possible 325 
treatment selection bias in the cohorts.(64)  A recent cohort study of patients with gram-326 
positive infective endocarditis demonstrated no significant difference in mortality between 327 
standard of care antibiotics and daptomycin, given at an average of ~8mg/kg in the E. 328 
faecalis group.(65)  The E. faecalis group treated with daptomycin had a significantly shorter 329 
length of stay compared to standard antibiotics (17.5 [13.5-19.5] vs. 31 [19.0-50.0]days, 330 
p=0.02).(65) Although small, this study also demonstrated no significant increase in adverse 331 
events with higher dose daptomycin. Our work demonstrates no statistically significant 332 
differences in any daptomycin regimen at 72h. High-dose daptomycin has some in vitro 333 
evidence to support its use in complicated enterococcal bacteremia and IE, as 10mg/kg, but 334 
not 6mg/kg, can prevent MIC increases in daptomycin non-susceptible S. aureus 335 
isolates.(66)  336 
In conclusion, daptomycin-containing regimens generally were more active against 337 
enterococcal isolates than linezolid throughout the experiments. The addition of rifampin to 338 
either linezolid or daptomycin did not significantly increase antibacterial activity in an in vitro 339 
sequestered high inoculum model of enterococcal endocarditis at 72h, and rifampin delayed 340 
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the bactericidal activity of daptomycin during the first 24 hours. The inhibition of bacterial 341 
RNA synthesis may be responsible for delaying the killing activities of cell wall active 342 
agents.(67) The addition of gentamicin improved the bactericidal activity of daptomycin most 343 
in the first 24h against E. faecalis, and increased linezolid activity at 72h against VRE 344 
faecium.  It is currently unclear how linezolid, a protein synthesis inhibitor, demonstrates 345 
improved activity in the presence of gentamicin.  This improved activity has also been 346 
observed in S. aureus and a vancomycin-resistant E. faecalis.(67-69)  We feel that our work 347 
supports the use of daptomycin 6 or 10mg/kg with 24 hours of gentamicin added for E. 348 
faecalis, as the most active therapy for enterococcal endocarditis. Other clinical studies 349 
demonstrate worse clinical outcomes when using rifampin in combination, while gentamicin 350 
adds activity in the first 24 hours only, and should be limited due to concerns for 351 
nephrotoxicity.  352 
A limitation of this study is the use of limited isolates.  In addition, we cannot conclude 353 
that our in vitro results will hold true with treatment durations longer than 72 hours.  Our 354 
findings with daptomycin and linezolid monotherapy are consistent with published clinical, in 355 
vitro and animal models. (7, 32, 70) The linezolid concentration in G. mellonella, while active, 356 
was lower than desired due to limits on available pharmaceutical concentrations. It is 357 
possible that the differences seen would not be significant if a higher concentration were 358 
used. While G. mellonella received doses targeting the free peak concentration achieved in 359 
humans, each drug was dosed only once, with survival being measured over 9 days, and 360 
pharmacokinetic information including metabolism and excretion are unknown.  361 
The results support daptomycin 6 or 10mg/kg, with gentamicin added for 24 hours, 362 
against enterococci in simulated endocardial vegetations. Nonetheless, our results should be 363 
applied to clinical practice with caution. Confirmation of these results in clinical studies is 364 
needed before these regimens can be adopted for use in the care of patients.      365 
366 
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TABLE 1.  MIC results using standard and high inocula for enterococcal isolates.  
a The standard inoculum was 5x105 CFU/mL, and the high inoculum was 5x109 CFU/mL.  Data for the high inoculum are presented 
parenthetically.  
NA = not applicable 
 
 
 
 
 
 
 
Antimicrobial 
MIC in mg/L a 
E. faecalis 
ATCC 29212 
E. faecium 
L2001 
Daptomycin      2 (4)      1 (8) 
Linezolid       1 (4)      1 (4) 
Gentamicin      16 (32)      16 (32)  
Rifampin      0.5 (0.5)      4 (16) 
Vancomycin       2     >256 
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Regimena 
Peak concentration (mg/L) Half-life (h) 
 Targeted Obtained Targeted Obtained 
Daptomycin 6mg/kg q24h 98.6 102.5 ± 1.96 8 7.92 ± 0.18 
Daptomycin 10mg/kg q24h 140.0 143.2 ± 1.94 8 7.87 ± 0.21 
Linezolid 600mg q12h 21.0 21.9 ± 0.86 6 6.52 ± 0.87 
Gentamicin 1.3mg/kg q12h 6.0 5.7 ± 0.51 2 2.08 ± 0.17 
Rifampin 300mg q8h 10.5 11.0 ± 1.23 4 3.60 ± 0.50 
 
 
TABLE 2. Values of mean targeted and obtained pharmacokinetic parameters obtained with 
simulated endocarditis vegetations (SEV) infection models ± standard deviation  
abased on a 75 kg patient 
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TABLE 3.  Inoculum change from starting inoculum of 5x109 CFU/g at 8, 24, and 72 h obtained in the SEV model. 
Note that positive values indicate growth. 
a Indicates statistically significant difference from growth control. 
 
 Mean change in bacterial density (log10 CFU/g) 
Antimicrobial E. faecalis  E. faecium  
 8h 24h 72h 8h 24h 72h 
Growth Control +1.13 +1.06 +1.29 +1.82 +1.93 +1.86 
Daptomycin 6mg/kg -2.07a -4.28a -5.07a -2.11a -4.56a -5.86a 
Daptomycin 6mg/kg+ rifampin -1.88a -2.99a -5.13a -1.84a -3.33a -5.30a 
Daptomycin 6mg/kg + gentamicin -4.36a -6.02a -6.15a -2.38a -4.96a -5.05a 
Daptomycin 10mg/kg -2.23a -4.17a -6.07a -3.57a -4.90a -5.63a 
Daptomycin 10mg/kg + rifampin -1.65a -3.48a -5.46a -2.09a -3.71a -5.41a 
Daptomycin 10mg/kg + gentamicin -2.32a -6.07a -5.67a -2.99a -4.08a -5.04a 
Linezolid  +0.02 -0.19 -0.95 +0.07 -1.08a -2.90a 
Linezolid + rifampin -0.07 -0.40 -1.96a +0.45 +0.48 -0.79 
Linezolid  + gentamicin +0.13 -0.15 -0.88a -0.14 -0.67a -4.08a 
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Growth Control 
 
Linezolid 
Linezolid + gentamicin 
Linezolid + rifampin 300 
Linezolid + rifampin 900 
 
Daptomycin 6mg/kg 
Daptomycin 6 + rifampin 300 
Daptomycin 10 + rifampin 300 
Daptomycin 10 + gentamicin 
Daptomycin 10mg/kg 
Daptomycin 6 + rifampin 900 
Daptomycin 6 + gentamicin 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The activity (change in log10 CFU/g) of daptomycin- or linezolid- containing regimens against a) Enterococcus faecalis. 
(vancomycin- susceptible, gentamicin- susceptible, rifampin- susceptible, daptomycin- susceptible, linezolid- susceptible) or b) 
Enterococcus faecium (vancomycin- resistant, gentamicin- susceptible, rifampin- resistant, daptomycin- susceptible, linezolid- 
susceptible). 
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Figure 3. Efficacy of compounds against E. faecalis
of a group of 16 larvae injected with E. faecalis followed by injection of the relative drug. 
Survival proportion with a) monotherapy of daptomycin 6mg/kg, daptomycin 10mg/kg, or linezolid vs controls. b) daptomycin 6mg/kg 
alone and in combination with rifampin  c) daptomycin 
combination with rifampin and e) linezolid alone or in combination with 
            
a) 
c) b) 
d) e) 
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6mg/kg alone or in combination with gentamicin d) linezolid alone or in 
gentamicin.  
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Figure 4. Efficacy of compounds against E. faecium on a G. mellonella infection model. Each line on the graph represents the survival 
of a group of 16 larvae injected with E. faecium followed by injection of the relative drug.  
Survival proportion with a) monotherapy of daptomycin 6mg/kg, daptomycin 10mg/kg, or linezolid vs controls. b) daptomycin 6mg/kg 
alone and in combination with rifampin  c) daptomycin 6mg/kg alone or in combination with gentamicin d) linezolid alone or in 
combination with rifampin and e) linezolid alone or in combination with gentamicin.  
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Antimicrobial and 
Human Dose 
Targeted free peak 
concentration (mg/L) 
Administered concentration 
in G. mellonella (mg/L) 
Daptomycin 6mg/kg 9.8 9.15 
Daptomycin 10mg/kg 14.0 13.07 
Linezolid 600mg 14.0 8.00a 
Gentamicin 1.3mg/kg 6.0 5.60 
Rifampin 300mg 2.6 2.50 
 
 
Table 4. Targeted vs. administered peak concentrations in G. mellonella models. 
a
 Linezolid concentrations were lower than targeted due to limits on the available pharmaceutical concentrations.  
